Latest Product Launches News

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

iCandy Interactive reports a remarkable 105% increase in net cash flow for Q4 2024 despite a 22% drop in cash receipts, driven by strategic expansions and operational efficiencies amid ongoing legal disputes.

Linius Technologies has appointed Ben Taverner as CEO and secured key partnerships and customers, including Brown University and Fujitsu, setting the stage for significant growth in FY25.

Ecofibre Limited reports a mixed financial performance for Q2 2025, highlighting significant debt reduction efforts and strategic restructuring to return to positive cash flows.

Connexion Mobility reports a robust half-year performance with 15% revenue growth and a 43% jump in net profit, driven by product innovation and expanding dealership engagement.

Propell Holdings has reported its first half-year cash profit since its 2021 ASX listing, driven by loan book growth and new product launches, despite a Q2 operating cash outflow.

One Click Group Limited reported a 42% increase in registered users and a 26% rise in revenue to $4.9 million in Q4 2024, while preparing to launch its new superannuation product in 2025.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

BirdDog Technology reports a strategic pivot with four next-generation product launches, a 20% price increase, and a robust cash position, despite a 13% revenue decline in H1 FY25.

EVE Health Group has completed the sale of its Robyndale tea tree property and relaunched its postbiotic concentrate range, signaling a strategic shift towards innovation and growth in the Australian market.